Operating
Other Working Capital
Year-over-year, this metric grew by 115.5%, from -$19.35M to $2.99M. Over 4 years (FY 2021 to FY 2025), Other Working Capital shows a downward trend with a 13.1% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
Positive changes suggest a source of cash from optimizing minor balance sheet items, while negative changes indicate cash is being tied up in these categories.
Detailed definition
The aggregate net change in miscellaneous operating assets and liabilities not specifically categorized in major line it...
Peer comparison
This is often used to reconcile net income to cash flow and varies based on a company's specific accounting classifications for 'other' items.
Metric ID:
change_in_other_working_capitalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.58M | -$16.78M | $3.68M | $7.40M | $10.44M | $2.78M | -$20.78M | -$6.28M | -$1.98M | $23.34M | -$17.47M | -$6.51M | -$11.78M | -$13.94M | -$6.76M | -$19.35M | -$18.51M | $6.40M | $0.00 | $2.99M |
| QoQ Change | — | <-999% | +121.9% | +101.2% | +41.1% | -73.4% | -848.4% | +69.8% | +68.5% | >999% | -174.8% | +62.7% | -80.9% | -18.3% | +51.5% | -186.3% | +4.4% | +134.6% | -100.0% | — |
| YoY Change | — | — | — | — | +562.5% | +116.5% | -665.6% | -184.9% | -118.9% | +740.5% | +16.0% | -3.8% | -496.1% | -159.7% | +61.3% | -197.2% | -57.1% | +145.9% | +100.0% | +115.5% |
Range-$20.78M – $23.34M
CAGR+14.5%
Avg YoY Growth-1.6%
Median YoY Growth+6.1%
Other Working Capital at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's other working capital?
- Alnylam Pharmaceuticals (ALNY) reported other working capital of $2.99M in Q1 2026.
- How has Alnylam Pharmaceuticals's other working capital changed year-over-year?
- Alnylam Pharmaceuticals's other working capital increased by 115.5% year-over-year, from -$19.35M to $2.99M.
- What is the long-term trend for Alnylam Pharmaceuticals's other working capital?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's other working capital has grown at a 13.1% compound annual growth rate (CAGR), from $19.24M to -$31.46M.
- What does other working capital mean?
- The cash impact from changes in various smaller business assets and obligations used in daily operations.